Miles Laboratories, founded in Elkhart, Indiana in 1884, became well known for patent medicines before transitioning into more regulated pharmaceutical production. Anti-Pain Pills occupy a transitional niche in pharmaceutical history — part legitimate pain relief, part relic of the cure-all marketing style of the early 20th century. While acetanilid does relieve pain and fever, chronic use was linked to methemoglobinemia and other toxic effects, leading to its replacement in most markets by safer alternatives like acetaminophen.

The combination of active analgesic (acetanilid), counterirritant (capsicum), and stimulant (caffeine) reflects a period when multi-ingredient painkillers were common and regulatory oversight was increasing but not yet fully modernized.

By modern standards, Miles Anti-Pain Pills are pharmacologically active and would have offered real pain relief. However, their broad marketing claims and inclusion of an unsafe primary ingredient place them squarely in the “transitional medicine” category — bridging the gap between the unregulated patent medicines of the 19th century and the standardized pharmaceuticals of the later 20th century.

Like Antikamnia, Miles’ Pain Pills relied on acetanilide for pain relief — a substance later recognized as dangerously toxic. The two brands together tell the story of how widely this “poison cure” was marketed before regulation caught up.